SITAGLIPTIN PHOSPHATE
Marketedupdated 2mo agoby Merck Sharp & Dohme LLC
Approvedcommunity read0 votes
indications
investigational
Type 2 Diabetes
all catalysts(3)
approval · 3
News(0)
no news has mentioned this drug yet
no news has mentioned this drug yet
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
comments(0)
5-min edit window · permanent after that